Repotrectinib is a targeted therapy. It blocks activities of TRK/ROS1/ALK fusion proteins. These are linked to lung cancer and some cancers with NTRK fusions.
It’s meant for patients with ROS1-positive NSCLC and those with NTRK-fusion cancers. The drug stops these proteins, which in turn keeps cancer cells from growing and surviving.There are capsules in a 40 mg strength. Here’s how you take them:You start with 160 mg once a day for the first 14 days, totaling up to 2,240 mg over two weeks.After those first 14 days, you’ll take 160 mg two times a day.The product comes in bottles with 60 capsules inside.Here’s what you need to know:40 mg capsulesIt’s a TRK/ROS1/ALK inhibitorDosage: First 14 days, 160 mg each day. After that, 160 mg two times a day.Each bottle holds 60 capsules
